In vivo blockade of platelet ADP receptor P2Y(12) reduces embolus and thrombus formation but not thrombus stability

M.A. Gestel, van; J.W.M. Heemskerk; D.W. Slaaf; V.V.T. Heijnen; R.S. Reneman; M.G.A. Oude Egbrink

doi:10.1161/01.ATV.0000057809.32354.22

In vivo blockade of platelet ADP receptor P2Y(12) reduces embolus and thrombus formation but not thrombus stability

M.A. Gestel, van, J.W.M. Heemskerk, D.W. Slaaf, V.V.T. Heijnen, R.S. Reneman, M.G.A. Oude Egbrink

Onderzoeksoutput: Bijdrage aan tijdschrift › Tijdschriftartikel › Academic › peer review

74 Citaten (Scopus)

Samenvatting

Objective— ADP is a key platelet agonist in thromboembolism. One of the receptors involved in ADP-induced platelet activation is the P2Y12 receptor, which is a target for antithrombotic drugs. Methods and Results— Here, we present first evidence for a differential role of this receptor in thrombus and embolus formation in vivo. Anesthetized rabbits were treated with the selective P2Y12 antagonists AR-C69931 MX (3 µg · kg · min-1 IV) or clopidogrel (25 mg/kg orally). Efficacy of these treatments was monitored by aggregation and thrombin generation measurements in blood samples ex vivo. Mesenteric arterioles were mechanically injured; thrombus growth and subsequent embolus formation were visualized by real-time intravital microscopy. AR-C69931 MX and clopidogrel significantly (P

Originele taal-2	Engels
Pagina's (van-tot)	518-523
Tijdschrift	Arteriosclerosis, Thrombosis, and Vascular Biology
Volume	23
Nummer van het tijdschrift	3
DOI's	https://doi.org/10.1161/01.ATV.0000057809.32354.22
Status	Gepubliceerd - 2003

Toegang tot document

10.1161/01.ATV.0000057809.32354.22

Citeer dit

@article{4499fa623b9b4ce890832a4362d3073f,

title = "In vivo blockade of platelet ADP receptor P2Y(12) reduces embolus and thrombus formation but not thrombus stability",

abstract = "Objective— ADP is a key platelet agonist in thromboembolism. One of the receptors involved in ADP-induced platelet activation is the P2Y12 receptor, which is a target for antithrombotic drugs. Methods and Results— Here, we present first evidence for a differential role of this receptor in thrombus and embolus formation in vivo. Anesthetized rabbits were treated with the selective P2Y12 antagonists AR-C69931 MX (3 µg · kg · min-1 IV) or clopidogrel (25 mg/kg orally). Efficacy of these treatments was monitored by aggregation and thrombin generation measurements in blood samples ex vivo. Mesenteric arterioles were mechanically injured; thrombus growth and subsequent embolus formation were visualized by real-time intravital microscopy. AR-C69931 MX and clopidogrel significantly (P",

author = "{Gestel, van}, M.A. and J.W.M. Heemskerk and D.W. Slaaf and V.V.T. Heijnen and R.S. Reneman and {Oude Egbrink}, M.G.A.",

year = "2003",

doi = "10.1161/01.ATV.0000057809.32354.22",

language = "English",

volume = "23",

pages = "518--523",

journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",

issn = "1079-5642",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "3",

}

TY - JOUR

T1 - In vivo blockade of platelet ADP receptor P2Y(12) reduces embolus and thrombus formation but not thrombus stability

AU - Gestel, van, M.A.

AU - Heemskerk, J.W.M.

AU - Slaaf, D.W.

AU - Heijnen, V.V.T.

AU - Reneman, R.S.

AU - Oude Egbrink, M.G.A.

PY - 2003

Y1 - 2003

N2 - Objective— ADP is a key platelet agonist in thromboembolism. One of the receptors involved in ADP-induced platelet activation is the P2Y12 receptor, which is a target for antithrombotic drugs. Methods and Results— Here, we present first evidence for a differential role of this receptor in thrombus and embolus formation in vivo. Anesthetized rabbits were treated with the selective P2Y12 antagonists AR-C69931 MX (3 µg · kg · min-1 IV) or clopidogrel (25 mg/kg orally). Efficacy of these treatments was monitored by aggregation and thrombin generation measurements in blood samples ex vivo. Mesenteric arterioles were mechanically injured; thrombus growth and subsequent embolus formation were visualized by real-time intravital microscopy. AR-C69931 MX and clopidogrel significantly (P

AB - Objective— ADP is a key platelet agonist in thromboembolism. One of the receptors involved in ADP-induced platelet activation is the P2Y12 receptor, which is a target for antithrombotic drugs. Methods and Results— Here, we present first evidence for a differential role of this receptor in thrombus and embolus formation in vivo. Anesthetized rabbits were treated with the selective P2Y12 antagonists AR-C69931 MX (3 µg · kg · min-1 IV) or clopidogrel (25 mg/kg orally). Efficacy of these treatments was monitored by aggregation and thrombin generation measurements in blood samples ex vivo. Mesenteric arterioles were mechanically injured; thrombus growth and subsequent embolus formation were visualized by real-time intravital microscopy. AR-C69931 MX and clopidogrel significantly (P

U2 - 10.1161/01.ATV.0000057809.32354.22

DO - 10.1161/01.ATV.0000057809.32354.22

M3 - Article

C2 - 12615691

SN - 1079-5642

VL - 23

SP - 518

EP - 523

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

IS - 3

ER -

In vivo blockade of platelet ADP receptor P2Y(12) reduces embolus and thrombus formation but not thrombus stability

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit